Saturday - October 10, 2026

Businesses Are Rethinking When to Hire a Full-Time CFO – Here’s What That Means for Consultants, The Expert CFO Says

The Expert CFO explains how businesses are increasingly using fractional CFOs before transitioning to full-time financial leadership. Rather than replacing full-time CFO roles, fractional engagements can help businesses build financial systems and prepare for future hiring. The shift also creates … Continue reading →

Law Firms Without a Dedicated Controller Are Taking On Unnecessary Trust Accounting Risk, K-38 Consulting Warns

K-38 Consulting warns that law firms without dedicated accounting oversight may face unnecessary trust accounting risks, including commingling, inaccurate client ledgers, missed reconciliations, and delayed fee transfers. The firm recommends consistent bookkeeping, monthly three-way reconciliation, and stronger accounting infrastructure as … Continue reading →

Law Firm Succession Planning Has a Financial Blind Spot Only a CFO Can Close, K-38 Consulting Warns

K-38 Consulting explains why law firm succession plans often overlook critical financial planning for partner buyouts, retirement obligations, and revenue transitions. With many firms facing aging partners, the firm recommends early cash flow modeling, structured funding, and realistic client-retention planning … Continue reading →

Diembassy Launches AI Adoption Internship Program to Foster Workforce Readiness Through Structured Upskilling for Professionals Worldwide

Diembassy Inc. has launched its AI Adoption Internship Program, a three-month professional development initiative designed to help working professionals build practical AI adoption skills through structured training and hands-on tasks aligned with their areas of expertise. Initially launched with professionals … Continue reading →

VivoSim Labs (NASDAQ: VIVS) Targets Complex ADC Drug Toxicity With Human 3D Biology

Dallas TX – September 30, 2026 – Antibody-drug conjugates are designed to deliver powerful cancer-killing payloads directly to targeted cells, but their precision comes with significant development complexity. For VivoSim Labs Inc. (NASDAQ: VIVS), that complexity could represent an important test—and … Continue reading →